Cardiovascular Research Group, Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK.
Farr Institute, Institute of Population Health, University of Manchester, Manchester, UK.
Eur Heart J. 2015 Jul 1;36(25):1618-28. doi: 10.1093/eurheartj/ehv113. Epub 2015 Apr 20.
This study aims to evaluate temporal changes in stroke complications and their association with mortality and MACE outcomes in a national cohort of patients undergoing percutaneous coronary interventions (PCIs) in England and Wales.
A total of 426 046 patients who underwent PCI in England and Wales between 2007 and 2012 in the British Cardiovascular Intervention Society (BCIS) database were analysed. Statistical analyses were performed evaluating the rates of stroke complications according to the year of PCI and multiple logistic regressions were used to evaluate the odds of 30-day mortality and in-hospital major adverse cardiovascular events (MACE; a composite of in-hospital mortality, myocardial infarction or re-infarction, and revascularization) with stroke complications. Four hundred and thirty-six patients (0.1%) sustained an ischaemic stroke/TIA complication and 107 patients (0.03%) sustained a haemorrhagic stroke complication. Ischaemic stroke/TIA complications increased non-linearly from 0.67 (95% CI 0.47-0.87) to 1.14 (0.94-1.34) per 1000 patients between 2007 and 2012 (P = 0.006), whilst haemorrhagic stroke rates decreased non-linearly from 0.29 (0.19-0.39) to 0.15 (0.05-0.25) per 1000 patients in 2012 (P = 0.009). Following adjustment for baseline clinical and procedural demographics, ischaemic stroke was independently associated with both 30-day mortality (OR 4.92, 3.06-7.92) and in-hospital MACE (OR 3.11, 1.83-5.27). An even greater impact on prognosis was observed with haemorrhagic complications (30-day mortality: OR 13.87, 6.37-30.21), in-hospital MACE (OR 13.50, 6.30-28.92).
Incident ischaemic stroke complications have increased over time, whilst haemorrhagic stroke complications have decreased, driven through changes in clinical, procedural, drug-treatment, and demographic factors. Both ischaemic and haemorrhagic strokes are rare but devastating complications with high 30-day mortality and in-hospital MACE rates.
本研究旨在评估英国和威尔士经皮冠状动脉介入治疗(PCI)患者队列中,随时间推移的卒中并发症变化及其与死亡率和主要不良心血管事件(MACE)结局的相关性。
在英国心血管介入学会(BCIS)数据库中,分析了 2007 年至 2012 年期间在英格兰和威尔士接受 PCI 的 426046 例患者。根据 PCI 年份评估卒中并发症发生率,并使用多变量逻辑回归评估卒中并发症与 30 天死亡率和院内主要不良心血管事件(MACE;包括院内死亡、心肌梗死或再梗死以及血运重建)的比值比。436 例(0.1%)患者发生缺血性卒中和 TIA 并发症,107 例(0.03%)患者发生出血性卒中并发症。2007 年至 2012 年期间,缺血性卒中和 TIA 并发症呈非线性增加,从每 1000 例患者 0.67(95%CI 0.47-0.87)增至 1.14(0.94-1.34)(P=0.006),而出血性卒中发生率呈非线性下降,从每 1000 例患者 0.29(0.19-0.39)降至 0.15(0.05-0.25)(P=0.009)。在校正基线临床和手术人口统计学因素后,缺血性卒中与 30 天死亡率(OR 4.92,3.06-7.92)和院内 MACE(OR 3.11,1.83-5.27)独立相关。出血性并发症对预后的影响更大(30 天死亡率:OR 13.87,6.37-30.21),院内 MACE(OR 13.50,6.30-28.92)。
随着时间的推移,缺血性卒中并发症不断增加,而出血性卒中并发症则有所减少,这是由临床、手术、药物治疗和人口统计学因素的变化驱动的。缺血性卒中和出血性卒中均为罕见但具有破坏性的并发症,其 30 天死亡率和院内 MACE 发生率均较高。